Acrivon (ACRV) COO Eric Devroe Sells 604 Shares

What Happened
Eric Devroe, Chief Operating Officer of Acrivon Therapeutics (ACRV), reported a sale of 604 shares on 2026-08-18 at $2.01 per share for a reported proceeds amount of $1,214. The sale was a disposition of vested restricted stock units (RSUs) to satisfy mandatory tax withholding. This was a sale (not a purchase) and is typically a routine, administrative transaction rather than an expression of investment conviction.

Key Details

• Transaction date and price: 2026-08-18 — 604 shares sold at $2.01 per share.
• Reported proceeds: $1,214 (as listed in the Form 4).
• Shares owned after transaction: Not specified in the filing.
• Footnote: F1 — shares were sold automatically to satisfy mandatory tax withholding upon RSU vesting.
• Filing date/timeliness: Form filed 2026-08-20 (two days after the transaction), which appears timely under Form 4 reporting rules.

Context
This was a tax-withholding sale tied to RSU vesting (an administrative "sell-to-cover"), which is common and does not necessarily signal insider sentiment about the company. No indication of option exercises, gifts, 10% owner transactions, or 10b5-1 trading plans in this filing.